Transaction #1420 · Form 4 · 0001710496-25-000002
Apimeds Pharmaceuticals US, Inc. · Stock award · Stock Option (right to buy)
Apimeds Pharmaceuticals US, Inc. · Transacted October 15, 2025 · Filed October 17, 2025
What does this filing report?
An SEC Form 4 filing for Apimeds Pharmaceuticals US, Inc. records a stock award involving Stock Option (right to buy) on October 15, 2025. The reported quantity was 215,000. The filing date is October 17, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company CIK
- 0001894525
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 215,000
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 215,000
- Ownership description
- Not reported
- SEC acceptance time
- Oct 17, 2025, 6:37 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Emerson Erik C. ↗
Chief Executive Officer · Director
CIK 0001710496
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock, par value $0.01 per share
- Underlying quantity
- 215,000
- Conversion / exercise price
- 1.92
- Exercise date
- Not reported
- Expiration date
- October 15, 2035
Filing footnotes & remarks
- F1
- The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's service to the issuer continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the issuer's incentive plan (the "Plan") to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full upon the occurrence of a Change in Control, as defined in the Plan.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.